NEW YORK (Fortune) -- As Genentech’s board weighs Monday’s $43.7 billion merger proposal from Roche, the South San Francisco biotech has one overarching reason to fall deeper into the arms of the Swiss drug maker that already owns most of its stock: Genentech’s “biological clock” is ticking.
